CG Oncology publishes Phase 3 BOND-003 Cohort C results for cretostimogene in The Lancet Oncology
CG Oncology on 27 July 2026 announced the publication of pivotal Phase 3 BOND-003 Cohort C results for its lead oncolytic immunotherapy cretostimogene grenadenorepvec in The Lancet Oncology , reinforcing the case for a bladder-sparing option in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without Ta/T1 disease.
Key efficacy findings from the intravesical monotherapy trial:
- Complete response (CR) rate: 75.5% (95% CI 66.3–83.2) achieved a CR at any time.
- Durability: 12- and 24-month duration of response of 64.2% and 60.1%, with median duration of response of 27.9 months — among the longer DORs reported in this setting.
- Bladder preservation: approximately 89% of patients maintained their bladders at 12 months and 81% at 24 months, offering a meaningful alternative to radical cystectomy.
- Safety: favourable safety and tolerability in a heavily pretreated real-world-representative population.
Lead author Mark D. Tyson II, M.D., of Mayo Clinic said the results "represent a potential shift in this treatment paradigm, underpinned by encouraging durability of response and bladder preservation outcomes." The publication follows CG Oncology's earlier pivotal readouts positioning cretostimogene as a bladder-sparing alternative in BCG-unresponsive NMIBC.
